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Summary  Aortic  valve  replacement  (AVR)  is  a  routine  procedure  for  decades  to  treat  patients
with  symptomatic  aortic  stenosis.  The  introduction  of  transcatheter  aortic  valve  implantation
(TAVI)  by  Professor  Alain  Cribier  has  paved  the  way  for  minimally  invasive  therapeutic  options
for  elderly  and  high-risk  patients  with  aortic  stenosis.  Transfemoral  and  transapical  aortic  valve
implantations  have  become  routine  procedures  in  many  centres  around  Europe.  TAVI  is  usually
being  performed  together  by  experienced  cardiologists  and  cardiac  surgeons  who  build  the
interdisciplinary  ‘Heart  Team’.  In  the  future,  improved  devices  together  with  advanced  fusion
imaging  will  lead  to  a  further  improvement  in  clinical  outcomes  for  the  sake  of  our  patients.
©  2012  Published  by  Elsevier  Masson  SAS.
MOTS  CLÉS Résumé  Le  remplacement  valvulaire  aortique  est  depuis  des  décennies  le  traitement  de
Open access under CC BY-NC-ND license.Sténose  aortique  ;
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valvulaire  aortique  ;
référence  du  rétrécissement  aortique  symptomatique.  Le  développement  des  valves  aortiques
percutanées  par  Alain  Cribier  a  ouvert  la  voie  d’une  approche  moins  invasive  pour  une  popula-
tion  âgée  et  à  risque  chirurgical  élevé.  Les  implantations  aortiques  percutanées  par  voie  trans-Transapical fémorale  ou  transapicales  sont  maintenant  réalisées  en  routine  dans  de  nombreux  centres  en
Europe.  Cette  procédure  est  d’habitude  réalisée  par  une  équipe  médico-chirurgicale  entraînée
réalisant  une  équipe  multidisciplinaire,  la  « Heart  Team  ».  Dans  le  futur,  les  améliorations
Abbreviations: AVI, aortic valve implantation; AVR, aortic valve replacement; CE, conformité européenne; CPB, cardiopulmonary bypass;
DA, Food and Drug Administration; TA, transapical; TAVI, transcatheter aortic valve implantation; TF, transfemoral; TEE, transoesophageal
chocardiography.
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technologiques  combinées  aux  progrès  de  l’imagerie  vont  permettre  d’améliorer  encore  les
résultats  dans  l’intérêt  de  nos  patients.
©  2012  Publié  par  Elsevier  Masson  SAS.
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Cet article est publié en Open Access sous licence CC BY-NC-ND.Background
Transcatheter  aortic  valve  implantation  (TAVI)  is  a  new
method enabling  off-pump  and  truly  minimally  invasive
treatment of  aortic  stenosis  by  means  of  retrograde
transfemoral, transsubclavian  or  transaortic  aortic  valve
implantation (AVI)  or  antegrade  transapical  AVI.  In  industri-
alized communities,  aortic  stenosis  is  the  most  frequently
acquired heart  valve  disease  and  if  untreated  is  associated
with high  mortality.  Medical  therapy  is  scarce  and  symp-
tomatic patients  have  a  high  attrition  rate  of  up  to  50%  in
the ﬁrst  year  [1].  Thus,  replacement  of  the  degenerated
valve is  the  only  treatment  option  that  improves  symptoms
and survival  [2,3].  For  decades,  conventional  surgical  aortic
valve  replacement  (AVR)  via  sternotomy,  using  cardiopul-
monary bypass  (CPB),  was  the  only  therapeutic  option  and
thus evolved  as  the  gold  standard.  The  number  of  elderly
patients presenting  with  aortic  stenosis,  however,  is  steadily
increasing in  parallel  with  improved  life  expectancy,  and
despite the  fact  that  surgical  AVR  can  be  performed  in  octo-
genarians with  good  results  [4—6],  there  are  many  patients
with increased  risk  proﬁles  for  surgical  AVR  due  to  advanced
age and  several  comorbidities.  In  the  past,  these  high-risk
patients were  not  even  referred  to  the  cardiac  surgeon  and
adequate treatment  was  denied  [7,8].
With  the  introduction  of  TAVI  by  Professor  Cribier  in  2002
[9] and  its  further  development  [10—13],  a  truly  minimally
invasive alternative  treatment  option  for  high-risk  patients
with severe  aortic  stenosis  has  evolved.  TAVI  allows  for  AVI
without cardioplegic  arrest  and  without  the  use  of  CPB.
Patients are  treated  on  a  beating  heart  and  the  new  prosthe-
sis is  implanted  within  the  calciﬁed  native  valve  leaﬂets  that
remain in  place  while  being  squeezed  aside.  Since  Professor
Cribier’s pioneering  initial  clinical  implantation  in  2002,  the
fascinating technical  achievements  of  transcatheter  tech-
niques that  facilitate  off-pump  aortic  valve  implantations
have developed  further.  Besides  the  mere  technical  factors
that enable  standardized  transcatheter  valve  implantations,
important additional  developments  have  occurred.  Most
importantly, cardiologists  and  cardiac  surgeons  have  come
together within  heart  teams  to  decide  jointly  upon  the  best
therapeutic options  for  each  individual  patient.  Joint  collab-
oration has  probably  been  the  most  important  improvement
over the  past  decade  and  will  lead  to  even  further  collabo-
rative efforts  for  the  sake  of  our  patients  in  the  future.
In  this  manuscript  we  will  focus  on  some  surgical  aspects
of these  exciting,  new  and  truly  minimally  invasive  treat-
ment options  for  patients  with  severe  aortic  stenosis.
Surgical aortic valve replacement (AVR) in
2012
Surgical  AVR  is  a  standardized  procedure  associated  with
low risks  in  most  referred  patients.  Use  of  CPB  allows  for
a
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btable  haemodynamics  throughout  the  procedure;  after
ortic cross-clamping  and  cardioplegic  cardiac  arrest  an
ortotomy is  performed  and  the  calciﬁed  cusps  are  excised.
ext, any  modern  xenograft  or  mechanical  prosthesis  is
mplanted using  standardized  suture  techniques,  which  are
ssociated with  a  very  low  risk  of  paravalvular  leakage.
Besides  conventional  sternotomy,  a  minimally  invasive
pproach can  be  routinely  applied  by  means  of  partial
pper sternotomy  (J-cut  in  the  third  or  fourth  intercostal
pace) or  parasternal  right  minithoracotomy  in  the  third
ntercostal space.  Access  closure  is  performed  with  sternal
ires and  a  standard  suturing  technique.  Current  results
ndicate low  mortality  rates  of  between  1%  and  3%  in  an
ll-comers population.
ranscatheter aortic valve implantation
TAVI)  from the beginnings to routine
linical  practice
ince  the  ﬁrst  clinical  patient  was  treated  by  Professor  Cri-
ier 10  years  ago,  TAVI  has  evolved  as  a  standard  therapy
or high-risk  elderly  patients  with  aortic  stenosis.  Initially,
AVI was  thought  to  be  a  transfemoral  procedure,  by  means
f a  femoral  venous  and  then  a transseptal  approach  ini-
ially and  via  a  retrograde  transfemoral  arterial  approach
ubsequently. Both  of  these  approaches  were  pioneered  by
rofessor Cribier.
Cardiac  surgeons  were  ‘non-believers’  in  this  new  tech-
ique throughout  the  early  years.  Different  thoughts,
owever, led  to  the  initiation  of  unparalleled  joint  efforts
etween cardiac  surgeons  and  cardiologists  in  order  to
urther develop  different  therapeutic  options  for  high-risk
lderly patients:  the  awareness  that  a  retrograde  trans-
emoral approach  may  not  be  suitable  in  some  patients,
specially in  presence  of  severe  peripheral  vascular  disease;
he thought  that  an  antegrade  approach  from  the  left  ven-
ricular apex  might  be  feasible;  and  the  belief  that  due  to
heir decades  of  experience  of  treatment  of  aortic  valve
isease, cardiac  surgeons  should  be  part  of  further  tech-
ological developments.  Mike  Mack  and  Fred  Mohr  started
n initiative  at  Edwards  Lifesciences  to  work  on  a  transapi-
al antegrade  access  platform  for  TAVI.  By  means  of  the
rst generation  of  the  Ascendra  transapical  delivery  system
Edwards Lifesciences,  Irvine,  CA,  USA),  initial  experimen-
al experience  was  gathered  in  November  and  December
004 at  the  laboratories  in  Irvine,  USA  and  Leipzig,  Germany.
ardiac surgeons  from  Dallas  (Mike  Mack  and  Todd  Dewey),
rankfurt (Gerhard  Wimmer-Greinecker  and  Mirko  Doss)  and
eipzig (Fred  Mohr  and  Thomas  Walther)  formed  a  partner-
hip to  develop  this  procedure  further.  After  ethical  approval
nd based  on  experiences  with  transfemoral  implantations,
nitial clinical  implantations  were  done  in  two  patients  in
eipzig in  December  2004,  with  the  support  of  Professor  Cri-
ier (Fig.  1).  Two  more  patients  were  treated  in  2005  in
176  
Figure 1. Professor Alain Cribier supporting the ﬁrst transapical
aortic valve implantations at the Heart Centre in Leipzig in Decem-
ber  2004, immediately after the procedure. This image shows him
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pacing. After  haemodynamic  recovery,  the  prepared  valveetween  Professors Mike Mack (Dallas, USA; left) and Friedrich W.
ohr  (Leipzig, Germany; right).
rankfurt  and  Leipzig.  However,  due  to  the  lack  of  a  26  mm
rosthesis, sufﬁcient  oversizing  was  not  applied  and  patients
herefore had  severe  paravalvular  leakage.  Further  experi-
ental evaluation  led  to  the  development  of  an  additional
uff around  the  SAPIEN  prosthesis,  to  provide  a  better  seal
gainst irregularities  at  the  aortic  annulus  and  thus  avoid
aravalvular leakage.  Towards  the  end  of  2005,  a  26  mm
APIEN prosthesis  became  available,  together  with  a  clear
oncept of  using  oversizing.  The  clinical  use  of  TA  AVI  was
estarted successfully  in  February  2006  in  Leipzig,  followed
y Vienna  and  Frankfurt.
urrent prostheses available for
ranscatheter  aortic valve implantation
TAVI)
ver  the  years,  different  prostheses  have  become  available
or performing  TAVI.  Initially  there  were  two  prosthe-
es, both  of  which  received  Conformité  Européenne  (CE)
pproval in  2008  and  then  became  commercially  available.
The  CoreValve® (Medtronic,  Minneapolis,  MN,  USA)  is  a
orcine pericardial  valve  mounted  on  a  self-expandable  niti-
ol stent,  which  is  available  in  three  sizes  (26,  29  and
1 mm);  the  delivery  system  allows  for  retrograde  implan-
ation only.  The  CoreValve® prosthesis  has  not  yet  obtained
ood and  Drug  Administration  approval.
The  SAPIEN  XTTM (Edwards  Lifesciences,  Irvine,  CA,  USA)
rosthesis consists  of  bovine  pericardial  leaﬂets  mounted
n a  balloon-expandable  cobalt-chromium  stent.  The  pros-
hesis  is  available  in  three  sizes  (23,  26  and  29  mm)  and
an be  implanted  using  either  the  retrograde  transfemoral
pproach or  the  antegrade  transapical  approach;  the  29  mm
alve is  for  the  transapical  approach  only.  A  large  random-
zed trial  for  FDA  approval  was  completed  recently  using
he previous  SAPIENTM valve  [14,15].  FDA  approval  has  been
ranted for  ‘inoperable’  patients  according  to  the  PARTNER
ohort B  study  and  will  probably  be  granted  for  high-risk  but
w
d
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operable’  patients  according  to  the  PARTNER  cohort  A  study
n spring  2012.
In October  2011,  two  second-generation  transcatheter
alves for  the  transapical  approach  obtained  CE  approval:
he JenaValveTM (JenaValve,  Munich,  Germany)  and  the  ACU-
ATE TATM valve  (Symetis,  Ecublens,  Switzerland).  Both  are
orcine valves  mounted  on  a  self-expandable  nitinol  stent.
he main steps of transcatheter aortic
alve  implantation (TAVI)
he  transfemoral  and  TA  techniques  allow  for  minimally
nvasive off-pump  AVI.  At  the  beginning  of  both  procedures  a
safety net’,  including  a  venous  back-up  wire  and  an  arterial
heath, should  be  placed  in  the  femoral  vessels  to  facilitate
mmediate conversion  (femoral-femoral  percutaneous  can-
ulation) to  CPB  should  any  complications  occur  during  the
rocedures [16].
For  transfemoral  AVI,  puncture  of  both  femoral  arteries
s necessary:  one  to  deliver  the  device  and  one  to  insert  the
igtail catheter.  For  balloon  valvuloplasty,  the  native  aortic
alve is  crossed  retrogradely.  Balloon  valvuloplasty  is  per-
ormed under  rapid  pacing  using  a transvenous  pacing  wire.
he prepared  valve  on  its  delivery  system  is  introduced  and
ositioned under  ﬂuoroscopic  control  after  haemodynamic
ecovery from  rapid  pacing.  The  valve  is  deployed  under  a
econd brief  episode  of  rapid  ventricular  pacing,  once  a  good
osition  is  conﬁrmed.  After  implantation,  the  valve  function
s assessed  by  either  ﬂuoroscopy  and/or  transoesophageal
chocardiography  (TEE).  If  any  signiﬁcant  paravalvular  leak
s noticed,  it  is  possible  to  reballoon  the  valve  with  a  slightly
arger balloon.  For  femoral  artery  closure  after  removing
he delivery  sheath,  a  closure  device  such  as  Prostar  XLTM
Abbott  Vascular  Devices,  Redwood  City,  CA,  USA)  can  be
sed. Surgical  closure  of  the  femoral  artery  is  an  alternative
ption.
The transfemoral  approach  allows  for  a  percutaneous
rocedure, which  can  be  performed  under  local  anaesthe-
ia and  then  without  TEE  control.  The  drawbacks  are  the
etrograde access  with  relatively  long  access  wires  and  the
ecessity to  cross  the  aortic  arch  retrogradely,  thus  risking
troke and  leading  to  quite  difﬁcult  valve  positioning  in  some
atients.
The transapical  AVI  approach  is  performed  through  a  5  cm
hort left  anterolateral  minithoracotomy  at  about  the  mid-
lavicular line  in  the  ﬁfth  or  sixth  intercostal  space.  After
he pericardium  is  opened,  the  apex  is  secured  with  two
eﬂon-pledgeted purse-string  sutures.  The  apex  can  then
e punctured,  allowing  for  straightforward  antegrade  valve
mplantation.  The  native  aortic  valve  is  crossed  antegradely
ith a  soft  guidewire,  which  is  then  changed  to  a super-stiff
ire positioned  down  into  the  descending  aorta.  A  pigtail
atheter is  positioned  just  above  the  aortic  valve  through
he arterial  sheath  of  the  ‘safety  net’.
The  apical  guidewire  is  used  for  the  valvuloplasty  balloon
nd the  valvuloplasty  is  performed  under  rapid  ventricularith its  delivery  system  is  inserted  through  the  apex  and
eployed under  ﬂuoroscopic  guidance.  Valve  function  and
osition are  again  assessed  by  TEE  and  ﬂuoroscopy.  Also,  for
177
Figure 2. The Symetis ACURATE TATM prosthesis: nitinol stent
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approval on  01  October  2011  and  is  a  porcine  root  valve
sewn on  a  nitinol  self-expandable  stent  (Fig.  3).  An  outer
pericardial patch  mounts  the  stent  as  a  so-called  skirt.Surgical  perspectives  of  TAVI  
TA-delivered  valves,  reballooning  might  be  indicated  in  case
of  signiﬁcant  paravalvular  leaks.  After  removal  of  the  sheath
and the  guidewire,  the  apex  is  closed  with  the  prepared
purse-string sutures.  Detailed  step-by-step  descriptions  for
both TAVI  approaches  have  been  published  earlier  [17,18].
The  transapical  approach  offers  some  potential  advan-
tages, such  as  the  short  distance  between  the  apex  and  the
aortic valve,  which  allows  for  very  precise  implantation.  As
opposed to  the  transfemoral  approach,  where  the  sheath
diameter is  limited  to  the  diameter  of  the  femoral  arteries,
with the  transapical  approach  there  is  no  limitation  to
sheath diameter.  The  avoidance  of  the  retrograde  crossing
of the  aortic  arch  may  be  advantageous  and  may  translate
into a  lower  stroke  rate  with  the  transapical  approach.
Transaortic  [19]  and  transsubclavian  [20]  AVI  have  been
introduced as  two  alternative  approaches  for  implanting
the CoreValve® prosthesis  in  patients  where  a  transfemoral
approach is  not  possible  due  to  pronounced  peripheral
vascular disease.  After  performing  either  an  upper  partial
sternotomy or  a  parasternal  minithoracotomy,  the  ascending
aorta is  punctured  for  the  transaortic  approach,  while  for
the transsubclavian  approach  the  subclavian  artery  is
exposed by  surgical  cut-down.  For  both  approaches,  the
valve is  implanted  retrogradely  in  an  analogous  manner  to
the transfemoral  approach.
Focus on the newly approved devices
ACURATE TATM
The  Symetis  ACURATE  TATM valve  obtained  CE  approval  on
01 October  2011  and  is  designed  for  transapical  use,  with
a transfemoral  pivotal  trial  starting  in  2012.  It  is  a  reg-
ular porcine  valve  on  a  proprietary  diabolo-shaped  nitinol
stent (Fig.  2),  is  available  in  three  sizes  (S-23  mm,  M-25  mm
and L-27  mm)  and  can  be  implanted  in  patients  with  annu-
lus diameters  between  21  and  27  mm.  The  prosthesis  is
deployed in  a  two-step  technique  and  has  some  unique  fea-
tures, which  allow  for  easy  positioning  and  implantation
and might  reduce  the  incidence  of  paravalvular  leaks.  The
‘stabilization arches’  (Fig.  2)  form  the  upper  part  of  the
prosthesis; they  are  released  in  the  ascending  aorta  and
prevent tilting  of  the  valve  during  deployment.  The  ‘upper-
crown’ is  located  just  above  the  valve  prosthesis  (Fig.  2);  it
allows for  intuitive  positioning  and  is  pulled  inside  the  aortic
annulus. The  stent  body  is  coated  by  a  polyethylene  tereph-
thalate skirt  to  minimize  the  risk  of  paravalvular  leaks.  The
stent commissures  are  visible  while  the  valve  is  crimped
under ﬂuoroscopy  and  can  be  anatomically  aligned  with  the
native commissures.
The device  is  inserted  using  a  sheathless  technique
through the  apex  and  advanced  into  supra-annular  position
controlled by  two  radiopaque  markers  at  the  level  of  the
valve. Step  one  of  the  implantation  is  performed  by  ﬁrst
releasing the  ‘stabilization  arches’  and  the  ‘upper-crown’.
This step  is  reversible  if  any  problems  occur  during  this  initial
positioning period.  For  step  two,  the  operator  pulls  slightly
on the  device  to  position  the  valve  inside  the  annulus.  The
‘upper-crown’ will  be  anchored  in  the  calciﬁed  annulus,
which gives  the  operator  tactile  feedback  for  positioning.
Step two  results  in  complete  deployment  of  the  valve  and
F
(ncluding stabilization arches, ‘upper-crown’ and body of the valve
tent  covered by a skirt. Porcine aortic valve leaﬂets are used.
he  delivery  system  can  be  removed.  A  detailed  overview
f the  implantation  technique  has  been  published  recently
21].
enaValveTM
he  transapical  JenaValveTM [22]  system  also  obtained  CEigure 3. The JenaValveTM, a nitinol frame with speciﬁc feelers
arrow), which allow for ﬁxation at the three native calciﬁed cusps.
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 transfemoral  system  is  under  development.  The  valve
s available  in  three  sizes  (23,  25  and  27  mm)  allowing
or implantation  in  patients  with  an  aortic  annulus  diam-
ter between  21  and  27  mm.  The  unique  feature  of  the
enaValveTM is  the  release  of  three  feelers  of  the  stent  in  the
rst step  of  implantation  (Fig.  3).  These  feelers  are  placed
n the  native  sinuses  and  embrace  them,  which  allows
or anatomically  correct  positioning  and  provides  active
xation of  the  valve.  In  a  second  step,  the  valve  is  partially
eleased and  valve  function  is  achieved  immediately.  Steps
ne and  two  are  completely  reversible.  Once  step  three  is
erformed the  valve  is  fully  deployed.
linical results
AVI  is  a  standardized  reproducible  technique  that  can  be
erformed safely  in  high-risk  patients.  Overall  mortality
ates published  by  experienced  centres  vary  from  3%  to  11%
14,15,23—26]. This  wide  range  in  mortality  rates  is  best
xplained by  patient  selection;  for  example,  most  of  the
atients included  in  the  PARTNER  trial  were  on  a  waiting  list
nd the  sicker  patients  may  have  died  before  TAVI  could  be
erformed, whereas  in  Europe,  TAVI  is  an  ‘all-comers’  tech-
ique with  even  emergency  TAVI  procedures.  Furthermore,
trict selection  criteria  clearly  lead  to  different  outcomes.
More  recent  results  have  been  presented  from  the
ARTNER continued  access  registry.  A  total  of  843  high-risk
atients (Society  of  Thoracic  Surgeons  score  risk  for  mor-
ality, 12.3%)  received  transapical  AVI  between  September
009 and  September  2011;  their  overall  risk  proﬁle  was  simi-
ar to  those  patients  who  were  included  in  the  transapical
rm of  the  PARTNER  trial.  Thirty-day  mortality  decreased
rom 8.7%  to  8.2%  and  1-year  mortality  decreased  from
9.1% to  23.6%  in  this  high-risk  patient  cohort.  In  parallel,
he risk  of  stroke  decreased  from  7%  (PARTNER)  to  2%  (con-
inued access)  at  30  days  and  from  10.8%  to  3.7%  at  1  year.
hese improvements  clearly  indicate  that  transapical  AVI
ould be  established  as  a  reliable  and  valuable  therapeutic
ption in  high-risk  patients  in  the  USA,  quite  similar  to  the
uropean experience.
None  of  the  currently  published  data  allows  a  preference
o be  had  for  either  the  transapical  or  the  transfemoral
pproach, due  to  the  fact  that  there  is  no  clinical  evidence
n favour  of  transfemoral  or  TA.  Many  centres,  however,
reat their  patients  with  a  ‘transfemoral-ﬁrst’  strategy
nd transapical  is  only  performed  in  patients  where  trans-
emoral is  not  possible.  This  results  in  negative  patient
election for  transapical  patients,  reﬂected  in  the  usually
igher-risk proﬁle  and  therefore  certainly  worse  outcome
f transapical  patients  [14,15,26—30].  Although  the  risk
roﬁle is  usually  higher  in  transapical  patients,  with  more
requent peripheral  vascular  disease,  there  is  a  trend
owards lower  stroke  rates  for  transapical  [28,29,31],  most
ikely  due  to  the  avoidance  of  the  retrograde  crossing  of
he aortic  arch.  Also  disturbances  of  the  conducting  system
eem to  be  more  frequent  after  transfemoral  AVI,  resulting
n a  trend  towards  a  higher  incidence  of  postprocedural
acemaker implantations  after  transfemoral  AVI,  with  this
rend becoming  statistically  signiﬁcant  when  using  the
oreValve® [26,27,29,32—34].  The  rates  of  postoperative
ortic regurgitation  more  than  1+  vary  between  4%  and
T
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8%  [14,15,26,27,31,34—38]  and  the  incidence  of  aortic
egurgitation should  always  be  kept  in  mind  when  talking
bout widening  the  indication  for  TAVI  to  include  younger
atients with  lower-risk  proﬁles.  The  very  good  results  after
onventional minimally  invasive  AVR  in  patients  with  low-
o-moderate risk  should  also  be  considered  when  discussing
AVI procedures  in  lower-risk  patients.  A  mortality  rate
etween 0%  and  approximately  3%  can  be  achieved  with
o relevant  incidence  of  aortic  regurgitation  more  than  1+
39—42].
erspectives
AVI  has  evolved  over  recent  years  as  a  standard  procedure
o treat  elderly  high-risk  patients  with  aortic  stenosis  using  a
etrograde transfemoral  approach  or  an  antegrade  transapi-
al approach.  In  parallel,  interdisciplinary  heart  teams,  led
y cardiologists  and  cardiac  surgeons,  have  been  established
t many  sites  to  strive  for  optimized  patient  treatment.
hese joint  efforts  are  one  of  the  most  beneﬁcial  ‘side
ffects’ of  the  initiation  of  TAVI.  All  medical  disciplines
nvolved in  the  treatment  of  sick  patients  work  together
o obtain  the  best  individual  solutions.  In  the  future,  cross
raining within  these  heart  teams  (e.g.  a  cardiologist  per-
orming transapical  AVI  and  a  cardiac  surgeon  performing
ransfemoral AVI,  both  with  the  support  of  the  other  col-
eague) should  be  further  developed.  Also,  a  joint  training
rogramme aimed  at  developing  ‘structural  heart  disease
nterventionalists’ may  be  established  by  the  different  spe-
ialties.
We  will  see  further  technical  developments  in  the  com-
ng years.  Besides  further  miniaturization  of  the  devices,
t will  be  possible  eventually  to  better  avoid  paravalvular
eakage, by  means  of  hydrophilic  coatings  around  the  stent
f the  valves.  Retrievability  of  transcatheter  prostheses  will
urther enhance  the  safety  margin  during  implantations.
dvanced imaging  with  further  integration  of  different
odalities (angiography,  computed  tomography  and  TEE)  by
eans of  fusion  imaging,  will  lead  to  optimized  visibility  of
andmark structures  during  TAVI  procedures.
Regarding  the  transapical  approach,  we  will  see  devices
hat will  allow  for  standardized  apical  access  and  closure.
urther along,  a  percutaneous  transapical  approach  may
hen become  a  reality.
All  these  developments,  after  thorough  experimental
esting and  then  careful  clinical  introduction,  will  beneﬁt
ur patients.
onclusions
rom  a  surgical  perspective,  patients  with  symptomatic  aor-
ic stenosis  require  either  conventional  AVR  or  transcatheter
VI, both  aimed  at  establishing  haemodynamically  good  aor-
ic valve  function.  In  patients  with  a  low-to-moderate  risk
roﬁle, conventional  AVR  should  be  performed,  preferably
sing a  minimally  invasive  approach.  For  high-risk  patients,
AVI has  evolved  as  an  alternative  minimally  invasive
reatment option  with  good  results  using  a retrograde  trans-
emoral approach  or  an  antegrade  transapical  approach.  At
resent, there  is  no  evidence  that  one  approach  is  superior
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to  the  other.  Every  higher-risk  patient  should  be  discussed
individually in  an  interdisciplinary  heart  team.
Professor  Alain  Cribier  deserves  the  scientiﬁc  credit  as
the initiator  and  pioneer  of  all  of  these  developments.  As  a
result of  his  initiative,  TAVI  has  evolved  as  one  of  the  most
important developments  in  modern  cardiovascular  medicine
in recent  years.  We  truly  thank  him  for  all  his  support.
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